[Skip to the reading](#reading)

[The chapters](/#chapter-map) [Care routes](/care-chapter/) [Recovery care notebook ](/)

[The bill](/cost-chapter/) [Question sheet](/reader-questions/)

Recovery care notebook / Evidence

# Match the evidence to the claim you were given.

Write down the exact claim first. Is the offer describing a drug’s status, a result in a study or the care you would receive? Each calls for a different check.

Use the source for the question it can answer, then discuss your own treatment choice.

Choose a source by what you want to know.

| Your question | A source to read | What to ask next
| Is this product approved? | Food and Drug Administration (FDA) product records. | What is it approved to treat? Is the listed product a shot, a pill or something else?
| What supports a recovery claim? | The actual study being used to support that claim. | Which people took part in the study, what did it compare, and which result did it measure?
| How will the assessment work? | The care service’s written process and the relevant state rules. | How does the clinician learn enough about my problem?

## What the drug records tell you

No BPC-157 request for drug approval appeared in FDA’s public drug-approval database on September 26, 2026.

There was no approved BPC-157 product in the U.S. on that date. This finding alone does not tell us whether a pharmacy may legally prepare it.

FDA reviewed proposed ways of giving BPC-157 to people. It has too little information about safety in people to judge possible harm from those uses.

A June 2023 FDA letter alleged that a seller’s BPC-157 and TB-500 products were unapproved drugs sold in breach of federal law.

That letter concerned a particular seller. It was an enforcement allegation, not a court judgment. Ask for the record that supports the status of the exact preparation being offered.

## A meeting did not settle what pharmacies may make

An advisory committee is a panel that gives FDA advice.

The meeting discussed whether to add ingredients to a list that allows regular pharmacies to use them in medicines made to order.

At the July 2026 advisory meeting, BPC-157 and TB-500 were among the peptide ingredients on the agenda.

FDA staff recommended keeping those ingredients off that list. BPC-157, TB-500, semax, epitalon, MOTS-c and KPV received panel votes in favor, HHS’s October 30, 2026 draft says. FDA’s page has no meeting minutes, transcript or record of individual votes.

The panel gives advice; its vote cannot change the law. To change that list, FDA must complete a rule-making process that lets the public comment.

These records do not settle whether a pharmacy may legally make the exact preparation offered to you.

Ask the pharmacy to name the rule it relies on for that ingredient.

### Questions to take back to a claim

Did the study involve people with my problem? What was the comparison? How long did the study follow them? What remains unknown?

Sources and when we checked them

Drug approval records, the FDA letter and the meeting’s published records: September 26, 2026. Later decisions are not covered here.

- [Search FDA’s drug approval records](https://api.fda.gov/drug/drugsfda.json)
- [FDA’s ingredient concerns](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)
- [The FDA letter discussed here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/warrior-labz-sarms-655280-06122023)
- [Advisory meeting materials](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026)
- [Read FDA staff’s recommendation](https://www.fda.gov/media/193343/download)

[Earlier chapter Medicines](/medicine-chapter/) [Continue reading The bill](/cost-chapter/)

This notebook is a guide for weighing care choices; it offers neither clinical visits nor products.

[All chapters](/#chapter-map) [Cautions](/safety-chapter/) [Source guide](/source-guide/)